Opinion issued August 23, 2019
In The
Court of Appeals
For The
First District of Texas
————————————
NO. 01-19-00551-CV
———————————
IN RE PURDUE PHARMA L.P., ET AL., Relators
Original Proceeding on Petition for Writ of Mandamus
MEMORANDUM OPINION
Relators, Purdue Pharma L.P., Purdue Pharma Inc., The Purdue Frederick
Company, Johnson & Johnson, Janssen Pharmaceutica Inc. n/k/a Janssen
Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., Ortho-McNeil-Janssen
Pharmaceuticals, Inc. n/k/a Janssen Pharmaceuticals, Inc., Endo Health Solutions
Inc., Endo Pharmaceuticals Inc., Allergan plc f/k/a Actavis plc, Allergan Finance,
LLC f/k/a Actavis, Inc. f/k/a Watson Pharmaceuticals, Inc., Watson Laboratories,
Inc., Actavis LLC, Actavis Pharma, Inc. f/k/a Watson Pharma, Inc., Knoll
Pharmaceutical Co. and AbbVie Inc. (collectively “Manufacturer Defendants”),
have filed a petition for a writ of mandamus challenging the trial court’s orders
denying the Manufacturer Defendants’ first amended joint motions to dismiss the
claims of real parties in interest, the Counties of Dallas, Delta, Falls, Hopkins, and
Travis, under Texas Rule of Civil Procedure 91a.1
We deny the petition.
PER CURIAM
Panel consists of Justices Lloyd, Goodman, and Landau.
1
The underlying case is In re: Texas Opioid Litigation, Cause No. 2018-63587, in
the 152nd District Court of Harris County, Texas, the Honorable Robert K. Schaffer
presiding.
2